Stoke Therapeutics Inc. has granted stock options to Naomi Muse, the newly appointed Senior Vice President, Program Leadership and Management, and six other new employees. Ms. Muse received stock options to purchase 80,000 shares of common stock at an exercise price of $26.95 per share, equal to the closing price on November 17, 2025. The options vest over four years, with one-fourth vesting on the first anniversary of the vesting start date and the remainder vesting monthly over the following 36 months, contingent on continued employment. The options have a ten-year term and are subject to the company's 2023 Inducement Plan and relevant stock option agreements. Six additional new employees were granted options to purchase a total of 156,490 shares under similar terms.